Teva Launches AHZANTIVE Biosimilar in Europe
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Product Launch: Teva announced the launch of AHZANTIVE (aflibercept) in Europe on June 4, 2026, as a biosimilar to Eylea®, marking a significant expansion in the ophthalmology sector aligned with the company's Pivot to Growth strategy.
- Market Coverage: The pre-filled syringes of AHZANTIVE began rolling out in May 2026 across several European markets, including France, Germany, Spain, and the Netherlands, aimed at enhancing treatment options for patients with serious retinal diseases and providing healthcare professionals with additional therapeutic choices.
- Strategic Partnerships: Teva has established a semi-exclusive commercialization agreement with Klinge Biopharma GmbH and Formycon AG, reinforcing its market position in major parts of Europe and Israel, with plans to launch in additional markets later this year.
- Product Advantages: AHZANTIVE has demonstrated comparable efficacy, safety, and immunogenicity to the reference product Eylea®, receiving European Commission approval in 2025 for treating various serious retinal diseases, showcasing Teva's robust capabilities and market potential in the biosimilars sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 32.830
Low
29.00
Averages
35.71
High
40.00
Current: 32.830
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alvotech Resubmits Biologics License Applications for Biosimilars
- Application Resubmission: Alvotech announced the resubmission of Biologics License Applications for AVT05 and AVT06 to the FDA, with AVT05 being a biosimilar to Simponi® and AVT06 to Eylea®, demonstrating the company's ongoing commitment to the biosimilars market.
- Partnership Dynamics: The collaboration with Teva Pharmaceuticals allows Alvotech to focus on the development and manufacturing of AVT05 and AVT06 while Teva handles commercialization, which is expected to accelerate product launches and enhance market competitiveness.
- Quality System Enhancement: Following a routine FDA inspection in May 2026, Alvotech has strengthened its quality systems and manufacturing operations, indicating a sustained investment in improving production standards and compliance, which is likely to positively impact future regulatory approvals.
- Market Outlook: The resubmission of AVT05 and AVT06 is expected to undergo a six-month review period, and if approved, will provide significant opportunities for market share growth in the biosimilars sector, further solidifying Alvotech's position in the global biopharmaceutical industry.
See More
Teva Launches Eylea Biosimilar Ahzantive
- Product Launch: Teva Pharmaceutical Industries announced the launch of its Eylea biosimilar, Ahzantive, on Thursday, marking a significant expansion in its biopharmaceutical portfolio aimed at meeting growing market demand.
- Market Potential: Eylea is a drug used for treating eye diseases, and with strong market demand, Teva's introduction of this biosimilar is expected to generate new revenue streams and enhance its competitiveness in the biopharmaceutical sector.
- Strategic Importance: By launching Ahzantive, Teva can leverage its expertise in the generics field while further solidifying its position in the global pharmaceutical industry, especially as biologics become increasingly critical.
- Future Outlook: This new product launch may attract more patients to choose Teva's biosimilar, potentially driving an increase in the company's market share in the biopharmaceutical sector and improving overall financial performance.
See More
Teva Launches AHZANTIVE Biosimilar in Europe
- Product Launch: Teva announced the launch of AHZANTIVE (aflibercept) in Europe on June 4, 2026, as a biosimilar to Eylea®, marking a significant expansion in the ophthalmology sector aligned with the company's Pivot to Growth strategy.
- Market Coverage: The pre-filled syringes of AHZANTIVE began rolling out in May 2026 across several European markets, including France, Germany, Spain, and the Netherlands, aimed at enhancing treatment options for patients with serious retinal diseases and providing healthcare professionals with additional therapeutic choices.
- Strategic Partnerships: Teva has established a semi-exclusive commercialization agreement with Klinge Biopharma GmbH and Formycon AG, reinforcing its market position in major parts of Europe and Israel, with plans to launch in additional markets later this year.
- Product Advantages: AHZANTIVE has demonstrated comparable efficacy, safety, and immunogenicity to the reference product Eylea®, receiving European Commission approval in 2025 for treating various serious retinal diseases, showcasing Teva's robust capabilities and market potential in the biosimilars sector.
See More
Alvotech Resubmits Biologics License Applications for Biosimilars
- Resubmission of Applications: Alvotech has announced the resubmission of Biologics License Applications (BLAs) for biosimilars ATV05 and ATV06, targeting chronic inflammatory diseases and retinal diseases, demonstrating the company's ongoing commitment to the biopharmaceutical sector.
- Collaborative Development: Both ATV05 and ATV06 were developed in collaboration with Teva Pharmaceutical Industries, highlighting the strategic partnership aimed at addressing the growing demand in the biosimilars market.
- FDA Review Expectations: The resubmission follows the company's response to a post-application action letter from the FDA, with expectations for a six-month review period, aligning with regulatory timelines and potentially opening new market opportunities for Alvotech.
- Market Reaction: Alvotech's stock closed at $32.83 on Thursday, down 0.76%, but showed a pre-market increase of 0.52%, indicating market interest and potential confidence in the company's biosimilar applications.
See More
UroGen Pharma Settles Patent Dispute with Teva Pharmaceuticals
- Patent Dispute Resolution: UroGen Pharma has reached a settlement with Teva Pharmaceuticals to resolve a patent dispute over its cancer therapy Jelmyto, ensuring UroGen's market exclusivity in the U.S. until April 15, 2027.
- Market Access Arrangement: As part of the settlement, Teva will receive a non-exclusive license to market its generic version starting September 15, 2030, pending FDA approval, which will provide Teva with a new revenue stream.
- Litigation Dismissal: The parties will request the court to dismiss the litigation with prejudice, meaning similar claims cannot be refiled, thereby reducing future legal risks and uncertainties.
- Market Impact Assessment: This settlement not only protects UroGen's market share but may also influence Teva's branding strategy, marking a further expansion into the generic drug market and enhancing its competitiveness in cancer treatment.
See More
Teva CEO to Participate in Goldman Sachs Healthcare Conference
- Goldman Sachs Conference Participation: Teva's CEO Richard Francis will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026, starting at 8:00 A.M. Eastern Time, showcasing the company's strategic direction in the healthcare sector.
- Investor Relations Transparency: The conference will be webcast live on Teva's Investor Relations website, with archived versions available within 24 hours post-event, enhancing communication between the company and its investors by providing timely updates.
- Company Transformation Strategy: Teva is transforming into a leading innovative biopharmaceutical company, committed to addressing patient needs through its world-class generics business, demonstrating its innovation capabilities in neuroscience and immunology.
- Caution on Forward-Looking Statements: Teva cautions investors regarding its forward-looking statements, highlighting that future performance may be influenced by various risks and uncertainties, ensuring that investors maintain a cautious outlook on the company's future developments.
See More
Alvotech Resubmits Biologics License Applications for Biosimilars
- Application Resubmission: Alvotech announced the resubmission of Biologics License Applications for AVT05 and AVT06 to the FDA, with AVT05 being a biosimilar to Simponi® and AVT06 to Eylea®, demonstrating the company's ongoing commitment to the biosimilars market.
- Partnership Dynamics: The collaboration with Teva Pharmaceuticals allows Alvotech to focus on the development and manufacturing of AVT05 and AVT06 while Teva handles commercialization, which is expected to accelerate product launches and enhance market competitiveness.
- Quality System Enhancement: Following a routine FDA inspection in May 2026, Alvotech has strengthened its quality systems and manufacturing operations, indicating a sustained investment in improving production standards and compliance, which is likely to positively impact future regulatory approvals.
- Market Outlook: The resubmission of AVT05 and AVT06 is expected to undergo a six-month review period, and if approved, will provide significant opportunities for market share growth in the biosimilars sector, further solidifying Alvotech's position in the global biopharmaceutical industry.
See More
Teva Launches Eylea Biosimilar Ahzantive
- Product Launch: Teva Pharmaceutical Industries announced the launch of its Eylea biosimilar, Ahzantive, on Thursday, marking a significant expansion in its biopharmaceutical portfolio aimed at meeting growing market demand.
- Market Potential: Eylea is a drug used for treating eye diseases, and with strong market demand, Teva's introduction of this biosimilar is expected to generate new revenue streams and enhance its competitiveness in the biopharmaceutical sector.
- Strategic Importance: By launching Ahzantive, Teva can leverage its expertise in the generics field while further solidifying its position in the global pharmaceutical industry, especially as biologics become increasingly critical.
- Future Outlook: This new product launch may attract more patients to choose Teva's biosimilar, potentially driving an increase in the company's market share in the biopharmaceutical sector and improving overall financial performance.
See More
Teva Launches AHZANTIVE Biosimilar in Europe
- Product Launch: Teva announced the launch of AHZANTIVE (aflibercept) in Europe on June 4, 2026, as a biosimilar to Eylea®, marking a significant expansion in the ophthalmology sector aligned with the company's Pivot to Growth strategy.
- Market Coverage: The pre-filled syringes of AHZANTIVE began rolling out in May 2026 across several European markets, including France, Germany, Spain, and the Netherlands, aimed at enhancing treatment options for patients with serious retinal diseases and providing healthcare professionals with additional therapeutic choices.
- Strategic Partnerships: Teva has established a semi-exclusive commercialization agreement with Klinge Biopharma GmbH and Formycon AG, reinforcing its market position in major parts of Europe and Israel, with plans to launch in additional markets later this year.
- Product Advantages: AHZANTIVE has demonstrated comparable efficacy, safety, and immunogenicity to the reference product Eylea®, receiving European Commission approval in 2025 for treating various serious retinal diseases, showcasing Teva's robust capabilities and market potential in the biosimilars sector.
See More
Alvotech Resubmits Biologics License Applications for Biosimilars
- Resubmission of Applications: Alvotech has announced the resubmission of Biologics License Applications (BLAs) for biosimilars ATV05 and ATV06, targeting chronic inflammatory diseases and retinal diseases, demonstrating the company's ongoing commitment to the biopharmaceutical sector.
- Collaborative Development: Both ATV05 and ATV06 were developed in collaboration with Teva Pharmaceutical Industries, highlighting the strategic partnership aimed at addressing the growing demand in the biosimilars market.
- FDA Review Expectations: The resubmission follows the company's response to a post-application action letter from the FDA, with expectations for a six-month review period, aligning with regulatory timelines and potentially opening new market opportunities for Alvotech.
- Market Reaction: Alvotech's stock closed at $32.83 on Thursday, down 0.76%, but showed a pre-market increase of 0.52%, indicating market interest and potential confidence in the company's biosimilar applications.
See More
UroGen Pharma Settles Patent Dispute with Teva Pharmaceuticals
- Patent Dispute Resolution: UroGen Pharma has reached a settlement with Teva Pharmaceuticals to resolve a patent dispute over its cancer therapy Jelmyto, ensuring UroGen's market exclusivity in the U.S. until April 15, 2027.
- Market Access Arrangement: As part of the settlement, Teva will receive a non-exclusive license to market its generic version starting September 15, 2030, pending FDA approval, which will provide Teva with a new revenue stream.
- Litigation Dismissal: The parties will request the court to dismiss the litigation with prejudice, meaning similar claims cannot be refiled, thereby reducing future legal risks and uncertainties.
- Market Impact Assessment: This settlement not only protects UroGen's market share but may also influence Teva's branding strategy, marking a further expansion into the generic drug market and enhancing its competitiveness in cancer treatment.
See More
Teva CEO to Participate in Goldman Sachs Healthcare Conference
- Goldman Sachs Conference Participation: Teva's CEO Richard Francis will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026, starting at 8:00 A.M. Eastern Time, showcasing the company's strategic direction in the healthcare sector.
- Investor Relations Transparency: The conference will be webcast live on Teva's Investor Relations website, with archived versions available within 24 hours post-event, enhancing communication between the company and its investors by providing timely updates.
- Company Transformation Strategy: Teva is transforming into a leading innovative biopharmaceutical company, committed to addressing patient needs through its world-class generics business, demonstrating its innovation capabilities in neuroscience and immunology.
- Caution on Forward-Looking Statements: Teva cautions investors regarding its forward-looking statements, highlighting that future performance may be influenced by various risks and uncertainties, ensuring that investors maintain a cautious outlook on the company's future developments.
See More
